Legal Representation
Attorney
Stephanie Goeller
USPTO Deadlines
Next Deadline
2008 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2025-01-07)
Due Date
January 07, 2031
Grace Period Ends
July 07, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
29 events| Date | Code | Type | Description |
|---|---|---|---|
| Jul 3, 2025 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB |
| Jul 3, 2025 | FIMP | P | FINAL DISPOSITION PROCESSED |
| Apr 7, 2025 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Jan 25, 2025 | OPNX | P | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |
| Jan 8, 2025 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Jan 8, 2025 | OPNR | P | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |
| Jan 7, 2025 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Jan 7, 2025 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Nov 19, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Nov 19, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Nov 13, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Oct 5, 2024 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Sep 16, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Sep 16, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Sep 16, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Apr 23, 2024 | RFNT | P | REFUSAL PROCESSED BY IB |
| Apr 4, 2024 | RFRR | P | REFUSAL PROCESSED BY MPU |
| Apr 4, 2024 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Apr 3, 2024 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Apr 2, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Mar 27, 2024 | RFWR | P | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW |
| Mar 5, 2024 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Mar 4, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Mar 4, 2024 | DOCK | D | ASSIGNED TO EXAMINER |
| Dec 10, 2023 | ADCH | M | CHANGE OF NAME/ADDRESS REC'D FROM IB |
| Oct 27, 2023 | CHLD | M | CHANGE OF OWNER RECEIVED FROM IB |
| Aug 15, 2023 | MAFR | O | APPLICATION FILING RECEIPT MAILED |
| Aug 11, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Aug 10, 2023 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB |
Detailed Classifications
Class 001
Active chemical ingredients for use in the manufacture of pharmaceuticals for treating cancer, autoimmune disorders, infectious diseases and cardiovascular, pulmonary and neurological conditions; chemicals for use in industry and science; reagents for scientific apparatus for chemical or biological analyses being reagents for scientific and research use; protein in raw material form for scientific and medical research; biochemicals for in-vitro and in-vivo scientific use; biological preparations for use in industry and science; chemical preparations for use in industry; catalysts for chemical processes; diagnostic preparations for scientific use; diagnostic reagents for science or research use; stem cells for research purposes
Class 005
Pharmaceutical products for treating cancer, autoimmune disorders, infectious diseases and cardiovascular, pulmonary and neurological conditions; medical preparations for the treatment of cancer, autoimmune disorders, infectious diseases and cardiovascular, pulmonary and neurological conditions; veterinary preparations for vaccinating livestock; disinfectants; preparations for destroying vermin; fungicides; herbicides; dietetic food and beverages adapted for medical use; dietetic pet foods and beverages for veterinary use; food for babies; food supplements; medical plasters, medical dressings; medicines for treating cancer, autoimmune disorders, infectious diseases and cardiovascular, pulmonary and neurological conditions
Class 042
Research and development of new pharmaceutical products, such as antibodies, antibody-drug conjugates, fusion proteins and other recombinant proteins; providing information with respect to medical and scientific research in the field of pharmaceutical products; pharmaceutical research and development services; consultation with respect to pharmaceutical research; medical research; scientific research services for medical purposes in the field of pharmaceuticals; biomedical research services; scientific and medical research and development, namely, research and development in the field of medical preparations; design and development of testing and analysis methods for new pharmaceutical product development; scientific research in the nature of conducting clinical trials for others; analysis and evaluation of newly developed pharmaceutical products, such as antibodies, antibody-drug conjugates, fusion proteins and other recombinant proteins; analysis and evaluation of newly designed pharmaceutical products, such as antibodies, antibody-drug conjugates, fusion proteins and other recombinant proteins; stem cell research services; scientific research services for medical purposes in the field of proteins, antibodies, microorganisms and cells; product research; providing medical and scientific research information in the field of pharmaceutical products and clinical trials; providing information on the results of clinical research trials for pharmaceutical products; consultation with respect to pharmaceutical research and development; providing integrated development of pharmaceutical products, namely, research and development of pharmaceutical products, and scientific research in the nature of conducting clinical trials and studies for others
Classification
International Classes
001
005
042